Andrew Mitchell

Andrew Mitchell

Auto-generated profile, based on publicly available information

Andrew Mitchell

Department of Pathology, Hôpital Maisonneuve-Rosemont, University of Montreal, 5415 boulevard de l’Assomption, Montréal, Québec, H1T 2 M4, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Chest
Verified
Journal Article
Closed access
AMAndrew Mitchell
Andrew Mitchell
CMCaroline Meunier
Caroline Meunier
DODenise Ouellette
Denise Ouellette
TCThomas Colby
Thomas Colby

7 November 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
EMEric Marcotte
Eric Marcotte
PDPierre Dubé
Pierre Dubé
PDPierre Drolet
Pierre Drolet
AMAndrew Mitchell
Andrew Mitchell
SFSuzanne Frenette
Suzanne Frenette
Lucas SiderisLucas Sideris
Lucas Sideris
Background: Appendiceal peritoneal carcinomatosis (PC) is rare and its long-term prognosis is poor. The aim of this study was to evaluate the results of an aggressive treatment approach used in our institution for the last eight years. Methods: Data from all patients with PC arising from the appendix were prospectively collected and analyzed. Treatment consisted of complete surgical cytoreduction (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin (460 mg/m2) at 43°C over 30 minutes. Ronnett’s histologic classification was used for tumor grading. Results: Between February 2003 and April 2011, 78 patients underwent laparotomy with curative intent. The mean follow-up period was 33.7 months. A total of 58 patients received HIPEC, but 11 patients could not have CRS and received no HIPEC. Nine patients with a negative second-look surgery also received no HIPEC. The five-year overall survival for the entire cohort was 66.2%; 100% for the negative second-look patients, 77% for the HIPEC patients and 9% for the unresectable patients (P <0.0001). A total of 15 patients (25.9%) had isolated peritoneal recurrence, no patient had visceral recurrence only, and five patients (8.6%) had both. In regards to the five-year disease-free survival for the HIPEC patients, histologic grade (disseminated peritoneal adenomucinosis 100%, peritoneal mucinous carcinomatosis with intermediate features 40%, peritoneal mucinous carcinomatosis 20%; p =0.0016) and completeness of cytoreduction (CCR-0 56%, CCR-1 24%; P =0.0172) were prognostic factors. There was one postoperative mortality. The major complication rate for patients treated with HIPEC was 40%, including intra-abdominal abcess (17%), hemorrhage (12%) and anastomotic leak (10%). One patient in the HIPEC group experienced temporary grade II neuropathy and grade III thrombocytopenia. Conclusions: This therapeutic approach seems both feasible and safe in selected patients. Recurrence is, however, frequent and represents a challenge.

1 November 2012 in Clinical Neuropathology
Verified
Journal Article
Closed access
AMAndrew Mitchell
Andrew Mitchell
BSBernd W. Scheithauer
Bernd W. Scheithauer
JDJosée Doyon
Josée Doyon
MBMarie-Josée Berthiaume
Marie-Josée Berthiaume
MIMarc Isler
Marc Isler
The great majority of malignant peripheral nerve sheath tumors (MPNST) exhibit Schwannian differentiation. In recent years, a subset of perineurial MPNST (malignant perineurioma) has been identified based on their histologic, immunohistochemical and ultrastructural features. Immunopositivity for epithelial membrane antigen (EMA), glut-1 and claudin-1, is characteristic. Such tumors must be distinguished from benign perineurioma and a variety of atypical or malignant soft tissue tumors featuring EMA positivity. Herein, we report a perineurial MPNST involving the buttock of a 42-year-old woman. Nerve involvement was noted. The clinicopathologic features of reported examples are ummarized and key differential diagnoses are discussed.